09/04/2026
Introducing NeurOp, Inc., a clinical-stage biotechnology company developing medicines for CNS disorders including pain, stroke, subarachnoid hemorrhage and treatment-resistant depression.
ASAP is proud to highlight the groundbreaking work of our portfolio company NeurOp, whose science is reshaping how NMDA receptor inhibitors can be used to treat serious neurological and psychiatric conditions.
NMDA receptors are key to brain signaling, but overactivation can contribute to severe pain, stroke, SAH, major depression, and addiction. While inhibitors like ketamine show promise, their broad activity across receptor subtypes can cause significant side effects.
NeurOp is changing that.
⭐ Precision Targeting Through Selectivity
NeurOp’s technology focuses on GluN2B‑selective inhibition,one specific NMDA receptor subtype.
This targeted approach aims to deliver therapeutic benefit without the broad side‑effect profile seen in non‑selective inhibitors.
⭐ Disease Context‑Dependent Activity
NeurOp’s compounds are designed to become more potent in acidified brain environments, which occur in conditions like:
Severe pain, SAH, Stroke, Addiction‑related brain regions
This means treatment can be more effective exactly where the disease is active, reducing unnecessary impact elsewhere.
⭐ A Lead Candidate in Development
NeurOp’s lead compound, NP10679, is currently in clinical development and represents a new generation of NMDA inhibitor therapy; one built on precision, context‑dependence, and meaningful potential for patients.
ASAP is proud to support founders and technologies pushing the boundaries of neuroscience and developing solutions for conditions with urgent unmet need.
Explore more of our portfolio: 🔗 https://asap-invests.com/